258 related articles for article (PubMed ID: 8769685)
1. Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia.
Tsuda Y; Satoh K; Kitadai M; Takahashi T; Izumi Y; Hosomi N
Atherosclerosis; 1996 May; 122(2):225-33. PubMed ID: 8769685
[TBL] [Abstract][Full Text] [Related]
2. Effect of medication with pravastatin sodium on hemorheological parameters in patients with hyperlipoproteinemia.
Tsuda Y; Satoh K; Takahashi T; Kitadai M; Ichihara S; Ayada Y; Hosomi N; Kawanishi K; Sada Y; Yamamoto M
Int Angiol; 1993 Dec; 12(4):360-4. PubMed ID: 8207314
[TBL] [Abstract][Full Text] [Related]
3. Comment on: effect of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia.
Mikhailidis DP; Ganotakis ES; Winder AF
Atherosclerosis; 1996 Dec; 127(2):287-90. PubMed ID: 9125320
[No Abstract] [Full Text] [Related]
4. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
5. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.
Naoumova RP; Marais AD; Mountney J; Firth JC; Rendell NB; Taylor GW; Thompson GR
Atherosclerosis; 1996 Jan; 119(2):203-13. PubMed ID: 8808497
[TBL] [Abstract][Full Text] [Related]
6. Comparative effects of simvastatin and pravastatin on cholesterol synthesis in patients with primary hypercholesterolemia.
Feillet C; Farnier M; Monnier LH; Percheron C; Colette C; Descomps B; Crastes De Paulet A
Atherosclerosis; 1995 Dec; 118(2):251-8. PubMed ID: 8770319
[TBL] [Abstract][Full Text] [Related]
7. Effect of lovastatin on hemorheology in type II hyperlipoproteinemia.
Koppensteiner R; Minar E; Ehringer H
Atherosclerosis; 1990 Jul; 83(1):53-8. PubMed ID: 2390136
[TBL] [Abstract][Full Text] [Related]
8. Chronic hemorheological effects of the calcium antagonist nilvadipine in essential hypertension.
Tsuda Y; Satoh K; Kitadai M; Izumi Y; Takahashi T
Arzneimittelforschung; 1997 Aug; 47(8):900-4. PubMed ID: 9296274
[TBL] [Abstract][Full Text] [Related]
9. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia.
Branchi A; Rovellini A; Sommariva D; Gugliandolo AG; Fasoli A
Thromb Haemost; 1993 Aug; 70(2):241-3. PubMed ID: 8236126
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats.
Joles J; Willekes-Koolschijn N; Koomans H; Van Tol A; Geelhoed-Mieras T; Crommelin D; Van Bloois L; Krajnc-Franken M; Cohen L; Griffioen M
Lab Anim; 1992 Oct; 26(4):269-80. PubMed ID: 1447905
[TBL] [Abstract][Full Text] [Related]
11. Lovastatin alters blood rheology in primary hyperlipoproteinemia: dependence on lipoprotein(a)?
Koenig W; Hehr R; Ditschuneit HH; Kuhn K; Ernst E; Rosenthal J; Hombach V
J Clin Pharmacol; 1992 Jun; 32(6):539-45. PubMed ID: 1634641
[TBL] [Abstract][Full Text] [Related]
12. Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase.
Cohen LH; van Vliet A; Roodenburg L; Jansen LM; Griffioen M
Biochem Pharmacol; 1993 Jun; 45(11):2203-8. PubMed ID: 8517861
[TBL] [Abstract][Full Text] [Related]
13. Abnormalities of blood rheology in familial hypercholesterolaemia: effects of treatment.
Jay RH; Rampling MW; Betteridge DJ
Atherosclerosis; 1990 Dec; 85(2-3):249-56. PubMed ID: 2129320
[TBL] [Abstract][Full Text] [Related]
14. Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients.
Dujovne CA; Harris WS; Altman R; Overhiser RW; Black DM
Am J Cardiol; 2000 Feb; 85(3):350-3. PubMed ID: 11078305
[TBL] [Abstract][Full Text] [Related]
15. [The HMG-CoA reductase inhibitors simvastatin and pravastatin. No indication for side effects in use on humans].
Schmidt J; Schmitt C; Hockwin O
Fortschr Ophthalmol; 1991; 88(6):843-5. PubMed ID: 1794817
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of dyslipidemia of the elderly with simvastatin and pravastatin. Effectiveness and tolerance].
Panuccio D; Trabatti MR; Romani A
Clin Ter; 1994 May; 144(5):419-24. PubMed ID: 7924180
[TBL] [Abstract][Full Text] [Related]
17. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study).
Jones P; Kafonek S; Laurora I; Hunninghake D
Am J Cardiol; 1998 Mar; 81(5):582-7. PubMed ID: 9514454
[TBL] [Abstract][Full Text] [Related]
18. Hemorheologic profiles of plasma fibrinogen and blood viscosity from silent to acute and chronic cerebral infarctions.
Tsuda Y; Satoh K; Kitadai M; Takahashi T
J Neurol Sci; 1997 Mar; 147(1):49-54. PubMed ID: 9094060
[TBL] [Abstract][Full Text] [Related]
19. Hemorrheologic abnormalities in defined primary dyslipoproteinemias with both high and low atherosclerotic risks.
Otto C; Ritter MM; Richter WO; Minkenberg R; Schwandt P
Metabolism; 2001 Feb; 50(2):166-70. PubMed ID: 11229424
[TBL] [Abstract][Full Text] [Related]
20. Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors.
Kleinveld HA; Demacker PN; De Haan AF; Stalenhoef AF
Eur J Clin Invest; 1993 May; 23(5):289-95. PubMed ID: 8354335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
